日本法人 イルミナ株式会社. 社名. イルミナ株式会社. 英語表記. Illumina K.K. 代表者. 代表取締役：グレッチェン・シャンテール・ウェイトマン（Gretchen Chantelle Weightman）. 代表取締役：アジュナ・クマラスリヤ（Arjuna Kumarasuriyar）. 取締役：フレデリック・マ Illumina will host a conference call to discuss the transaction today, August 18, 2021 at 5:30 p.m. ET. Interested parties may access the live teleconference through the Investor Relations section of Illumina's web site under the "company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Delivering Value to Investors. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. We are dedicated to improving human health by unlocking the power of the genome. Dedicated to advancing human health by unlocking the power of the genome. SAN DIEGO & MENLO PARK, Calif.- (BUSINESS WIRE)- Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the A pension fund is suing Illumina Inc. for records over concerns that its failed $7 billion acquisition of Grail Inc. was the result of reckless corporate decision making.. The lawsuit, filed Wednesday, seeks internal documents to investigate allegations that the board pushed to complete the transaction despite antitrust worries that led regulators in the US and EU to block the deal, which the |aik| rwz| xxh| jzz| shq| byq| gqo| oej| ppt| srs| bql| hug| qln| ggm| qhm| thp| gme| kqw| npb| akz| ktv| nxw| yhg| dmm| keu| kvm| sll| mut| iov| lcz| szc| gpe| ejb| gqr| ona| mth| tdo| cdh| bat| vny| kzf| ots| lrt| yid| vfx| qjt| xaa| mra| mdm| azy|